核蛋白血清阳性检测轻症与无症状SARS-CoV-2感染:COVID-19疫苗接种后突破性感染的补充检测工具?
研究利用1,513名未接种COVID-19疫苗且经RT-qPCR检测者的多重免疫分析数据,评估核蛋白特异性IgG检测既往SARS-CoV-2感染的准确性,并描述230名辉瑞/BioNTech疫苗接种者的Spike S1与核蛋白IgG反应。结果显示核蛋白血清阳性对轻症COVID-19在症状出现后前两个月的敏感性为85%(95%CI 80-90%),无症状者为67%(50-81%);既往感染者接种后Spike S1 IgG中位水平较未暴露者高2.7倍(p=0.011)。
要点
- 核蛋白血清阳性检测轻症COVID-19症状后两个月敏感性85%(95%CI 80-90%)。
- 无症状感染者核蛋白血清阳性敏感性为67%(95%CI 50-81%)。
- 既往感染可使接种后Spike S1 IgG中位水平升高2.7倍(p=0.011)。
核心结论
- 核蛋白血清学应答可能有助于识别接种后的SARS-CoV-2感染,并可帮助解读COVID-19疫苗接种后的Spike S1 IgG,因为接种后短期内特别高的应答可由既往暴露史解释。
研究设计与样本
- 利用1,513名经SARS-CoV-2 RT-qPCR检测(352例阳性、1,161例阴性)且无COVID-19疫苗接种史个体的多重免疫分析数据,评估核蛋白特异性IgG检测既往感染的准确性;另描述230名COVID-19疫苗接种者(辉瑞/BioNTech)的Spike S1与核蛋白特异性IgG应答。
主要发现
- 核蛋白血清阳性对轻症COVID-19在症状出现后前两个月的敏感性为85%(95%CI 80-90%)。
- 核蛋白血清阳性对无症状感染者的敏感性为67%(95%CI 50-81%)。
- 经Spike S1血清阳性或RT-qPCR评估在接种前11个月内曾感染SARS-CoV-2者,首次剂量后≥14天Spike S1 IgG中位水平较未暴露者第二剂后≥7天高2.7倍(p=0.011)。
- 在未感染参与者中,疫苗接种不影响核蛋白特异性IgG浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With COVID-19 vaccine roll-out ongoing in many countries globally, monitoring of breakthrough infections is of great importance. Antibodies persist in the blood after a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Since COVID-19 vaccines induce immune response to the Spike protein of the virus, which is the main serosurveillance target to date, alternative targets should be explored to distinguish infection from vaccination. METHODS: Multiplex immunoassay data from 1,513 SARS-CoV-2 RT-qPCR-tested individuals (352 positive and 1,161 negative) without COVID-19 vaccination history were used to determine the accuracy of Nucleoprotein-specific immunoglobulin G (IgG) in detecting past SARS-CoV-2 infection. We also described Spike S1 and Nucleoprotein-specific IgG responses in 230 COVID-19 vaccinated individuals (Pfizer/BioNTech). RESULTS: The sensitivity of Nucleoprotein seropositivity was 85% (95% confidence interval: 80-90%) for mild COVID-19 in the first two months following symptom onset. Sensitivity was lower in asymptomatic individuals (67%, 50-81%). Participants who had experienced a SARS-CoV-2 infection up to 11 months preceding vaccination, as assessed by Spike S1 seropositivity or RT-qPCR, produced 2.7-fold higher median levels of IgG to Spike S1 ≥ 14 days after the first dose as compared to those unexposed to SARS-CoV-2 at ≥ 7 days after the second dose (p = 0.011). Nucleoprotein-specific IgG concentrations were not affected by vaccination in infection-naïve participants. CONCLUSIONS: Serological responses to Nucleoprotein may prove helpful in identifying SARS-CoV-2 infections after vaccination. Furthermore, it can help interpret IgG to Spike S1 after COVID-19 vaccination as particularly high responses shortly after vaccination could be explained by prior exposure history.
引用
- van den Hoogen LL, Smits G, van Hagen CCE, et al. Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination? Vaccine. 2022. PMID: 35287986. doi:10.1016/j.vaccine.2022.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。